Takara Bio, Sloan-Kettering to develop NHL gene therapy
Japanese biotech firm Takara Bio has announced a collaboration with Memorial Sloan-Kettering Cancer Center in the United States to begin the process of running a clinical trial for a non-Hodgkin's lymphoma therapy involving gene therapy.
The therapy in question will utilize Chimeric Antigen Receptor (CAR) technology, which has been in development by Memorial Sloan-Kettering since 2007. They have been exploring the efficacy of a CAR targeting CD19, a protein expressed on the surface of certain B lymphocytes. Until now, CD-19 CAR gene therapy has only undergone early-stage testing for certain patients with leukemia, with encouraging results.
Together, Takara Bio and Memorial Sloan-Kettering will apply for gene therapy clinical research in Japan by using Sloan-Kettering's previously gathered data on CD19 CAR, and Takada will develop the retrovirus vector necessary in gene therapy to gain access to the cell.
Source: Takara Bio
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
